The All India Institute of Medical Sciences in New Delhi has achieved a major milestone in stroke care by conducting India’s first dedicated clinical trial of an advanced brain stent designed to treat severe and life-threatening strokes.
The multi centre GRASSROOT trial evaluated the Supernova stent developed by Gravity Medical Technology and demonstrated excellent safety and efficacy outcomes in the treatment of severe strokes.
AIIMS Delhi served as the national coordinating centre and lead enrolling site for the trial, which was conducted across eight centres in the country. The study findings have been published in the Journal of Neurointerventional Surgery, part of the British Medical Journal group, highlighting the scientific significance of the work.
Earlier this year, data from the GRASSROOT trial were accepted by the Central Drugs Standard Control Organisation, following which the Supernova stent-retriever received regulatory approval for routine clinical use in India. This marks the first stroke device in the country to receive approval based entirely on a domestic clinical trial.
The successful trial and subsequent approval are being seen as a significant boost to the Make-in-India initiative in advanced medical devices, demonstrating that world-class clinical evidence can be generated within India while improving access to effective and affordable stroke care.
